Sales SEK 721m -13% vs. ABGSCe 824m Adj. EBITDA SEK 13.
Redeye provides an initial take of FlexQubes’ Q4 report.
Sales -7% vs ABGSCe, adj. EBITA -7% vs ABGSCe Outlook uncertain, '23e-'24e adj.
Profitability advanced in Q4 as plant productivity improved Scanfil Q4 top line grew 16% y/y to EUR ...
Redeye comments on Zordix Q4-report which saw revenue in line with expectations while EBITDA came in...
Recurring PTP SEK 55m vs ABGSCe at SEK 57m Q4'22: Rental income SEK 192m (1% vs ABGSCe 189m), NOI 13...
Raketech just released a solid Q4 report, and a better than expected start to the first quarter.
Redeye provides its initial take on Surgical Science’s Q4 2022 report, broadly aligning with our est...
Q4 results Arise delivered sales of SEK 106m, which was 10% below our expectations of SEK 118m.
Redeye is encouraged by Thunderful group’s Q4 2022 report.
Redeye is encouraged by the news that Zwipe starts the first proof-of-concept together with Civix fo...
UK and Germany both strong, and margins improve Alcadon reported Q4 sales of SEK 401m (+2% vs.
Redeye comments on Savelend’s Q4 results, which came in line in terms of revenues, while margins cam...
Redeye argues that the Q4 report was rather weak, but that the weakness fully orignates from externa...
Redeye comments on Freemelt’s Q4 results and the directed share issue.
Vow reports its H2 2022 results on 23 February. We expect key focus points to be developments in the...
Sales 15% better, EBIT 0% vs. ABGSCe We cut '23-'24e sales by 5-6% Lowered fair value range to SEK 6...
NOI estimates up by 3-4%, CEPS slightly negative Near-term focus on consolidation P/CEPS ~13x vs sec...
Redeye welcomes today's news that Acarix has received an important "breakthrough" order from the US ...
Ferroamp levererar rekordförsäljning i Q4 samtidigt som förlusten ökar.
